SCHEMBL4012896

SCHEMBL4012896

CCCc1cc(C(=O)CC)c(O)c(CCC)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.54
PPARA Q07869 5/20 0.54
HSP90AB1 P08238 2/20 0.40
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
XBP1 P17861 1/20 0.39
HIF1A Q16665 1/20 0.39
HMGCR P04035 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYSLTR2 Q9NS75 1/20 0.37
CYSLTR1 Q9Y271 1/20 0.37
PRKCI P41743 1/20 0.37
PTPN1 P18031 1/20 0.37
PTPN11 Q06124 1/20 0.37
LDHA P00338 2/20 0.36
LDHB P07195 2/20 0.36
KDM4E B2RXH2 1/20 0.36
UBE2N P61088 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4013279 0.85 PPARG (0.45) PPARGPPARAHSP90AB1MAPTLMNA
SCHEMBL10690373 0.84 MEN1 (0.53) PPARGPPARAMAPTLMNAMEN1
SCHEMBL4016040 0.80 PPARG (0.41) PPARGPPARALMNAHMGCRMEN1
SCHEMBL13924151 0.79 PPARA (0.38) PPARGPPARAHSP90AB1MAPTLMNA
SCHEMBL2855431 0.76 PPARG (0.46) PPARGPPARAHSP90AB1MAPTLMNA
SCHEMBL10560290 0.75 PPARG (0.43) PPARGPPARAHSP90AB1LMNAHIF1A
SCHEMBL13924211 0.75 PPARG (0.38) PPARGPPARAHSP90AB1MAPTLMNA
SCHEMBL4012223 0.74 PPARG (0.55) PPARGPPARAMAPTMEN1KMT2A
SCHEMBL4017548 0.74 HSP90AB1 (0.49) PPARGPPARAHSP90AB1MAPTLMNA
SCHEMBL28743467 0.73 PPARG (0.41) PPARGPPARAHSP90AB1LMNAHMGCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495020-B2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK & CO., INC. (US) 2009-02-24 US disclosed
US-7495020-B2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK & CO., INC. (US) 2009-02-24 US disclosed
US-7495020-B2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK & CO., INC. (US) 2009-02-24 US disclosed
US-7091230-B2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK & CO., INC. (US) 2006-08-15 US disclosed
US-20060122242-A1 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2006-06-08 US disclosed
EP-1366012-A4 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS MERCK & CO INC (US) 2005-11-02 EP disclosed
US-20040092596-A1 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2004-05-13 US disclosed
EP-1366012-A2 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS Merck & Co., Inc. (US) 2003-12-03 EP disclosed
WO-2002064094-A2 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122242-A1 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885HSP90AB1 877/4885
US-20040092596-A1 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885HSP90AB1 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.